Publication | Open Access
Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
41
Citations
3
References
2020
Year
Diabetes ManagementPrimary CareHealth PolicyHealth EconomicsDiabetesHealth InsuranceOutcomes ResearchPharmacoeconomicsHealth Care CostCost EffectivenessDiabetes MellitusCost SharingOut-of-pocket CostsEconomic EvaluationMedicinePublic HealthHealth Services ResearchMedicare Part D
This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.
| Year | Citations | |
|---|---|---|
Page 1
Page 1